Skip to content
value.today

Trius Therapeutics Inc

🇺🇸 San Diego, California, USABiotechnologyFounded 2007

Formerly RX3 Pharmaceuticals, Inc.

Total raised
$49 M
2 rounds on record
Latest round
$30 M
May 2011
First round on record
Nov 2009
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Trius Therapeutics Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2011$30 MNo. 2$10 to $50 million

Trius Therapeutics Inc: Raise no. 2, May 2011

Investors in this round

25 investors had bought by the notice of Jun 7, 2011: 25 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Trius Therapeutics Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$30 M of $44 M offered; $14 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$5 million to $25 million
Sales commissions
$1,809,750
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey Stein · Executive Officer, Director
  • John Finn · Executive Officer
  • John P. Schmid · Executive Officer
  • Kenneth S. Bartizal · Executive Officer
  • Michael R. Morneau · Executive Officer
  • Philippe S. Prokocimer · Executive Officer
  • Brenden R. O'Leary · Director
  • Brian G. Atwood · Director
  • David S. Kabakoff · Director
  • Karin S. Eastham · Director
  • Michael S. Powell · Director
  • Nina S. Kjellson · Director
  • Paul F. Truex · Director
  • Risa P. Stack · Director
  • Theodore R. Schroeder · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Piper Jaffray & Co. (CRD 665) · New York, New YorkSold in all US states

Remarks in the notice

  • On the amounts: “Includes amounts receivable by the issuer upon the exercise of warrants to purchase the Issuer's securities, assuming no cashless exercise. Such Warrants have not yet been exercised.”

Signed by John Schmid, Chief Financial Officer and Secretary. Source: SEC Form D, newest notice filed Jun 7, 2011. Read the notice at the SEC.

equity, optionsSEC
Nov 2009$19 MNo. 1$10 to $50 million

Trius Therapeutics Inc: Raise no. 1, Nov 2009

Investors in this round

11 investors had bought by the notice of Nov 12, 2009: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Trius Therapeutics Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$19 M of $30 M offered; $11 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey Stein · Executive Officer, Director
  • John Finn · Executive Officer
  • John Schmid · Executive Officer
  • Kenneth G. Bartizal · Executive Officer
  • Philippe G. Prokocimer · Executive Officer
  • Brian G. Atwood · Director
  • David Kabakoff · Director
  • Karin G. Eastham · Director
  • Michael G. Powell · Director
  • Nina G. Kjellson · Director
  • Paul Truex · Director
  • Risa Stack · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Schmid, CFO & Secretary. Source: SEC Form D, newest notice filed Nov 12, 2009. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Trius Therapeutics Inc had revenue between $5 million and $25 million when it filed its newest notice of a funding round (Jun 2011).

    SEC Form D (revenue range) · Jun 2011

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2011

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

11 named in official filings. Open an investor to see everything it has backed.

Investors in Trius Therapeutics Inc
InvestorKindAmountRoundRoleSource
InterWest Management Partners IX, LLCFund or asset managernot statednot statedHeld Series A-2 and B preferred stock (Form 3, 2010)SEC Form 3
InterWest Partners IX, LPFund or asset managernot statednot statedHeld Series A-2 and B preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Kpcb Pandemic & Bio Defense Fund LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2010)SEC Form 3
KPCB PBD Associates, LLCOthernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2010)SEC Form 3
KPCB PBD Founders Fund, LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Prism Venture Partners V-A LPVenture capitalnot statednot statedHeld Series A-2 and B preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Prism Venture Partners V L.P.Venture capitalnot statednot statedHeld Series A-2 and B preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Sofinnova Management VII, L.L.C.Fund or asset managernot statednot statedHeld Series A-2 and B preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Sofinnova Venture Partners VII L.P.Venture capitalnot statednot statedHeld Series A-2 and B preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Versant Side Fund III, L.P.Fund or asset managernot statednot statedHeld Series A-2 and B preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Versant Venture Capital III, L.P.Venture capitalnot statednot statedHeld Series A-2 and B preferred stock, 10% owner (Form 3, 2010)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 25 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Trius Therapeutics Inc
NameRoleNamed in
Jeffrey SteinExecutive officerJun 2011
John FinnExecutive officerJun 2011
John P. SchmidExecutive officerJun 2011
Kenneth S. BartizalExecutive officerJun 2011
Michael R. MorneauExecutive officerJun 2011
Philippe S. ProkocimerExecutive officerJun 2011
John SchmidExecutive officerNov 2009
Kenneth G. BartizalExecutive officerNov 2009
Philippe G. ProkocimerExecutive officerNov 2009
Brenden R. O'LearyDirectorJun 2011
Brian G. AtwoodDirectorJun 2011
David S. KabakoffDirectorJun 2011
Jeffrey SteinDirectorJun 2011
Karin S. EasthamDirectorJun 2011
Michael S. PowellDirectorJun 2011
Nina S. KjellsonDirectorJun 2011
Paul F. TruexDirectorJun 2011
Risa P. StackDirectorJun 2011
Theodore R. SchroederDirectorJun 2011
David KabakoffDirectorNov 2009
Karin G. EasthamDirectorNov 2009
Michael G. PowellDirectorNov 2009
Nina G. KjellsonDirectorNov 2009
Paul TruexDirectorNov 2009
Risa StackDirectorNov 2009